Clinical trials: sponsored by University of Oxford
Malaria, Plasmodium Falciparum
A Study of the Plasmodium Falciparum Malaria Vaccine Candidate Pfs48/45 in Matrix-M Adjuvant in the UK
This is an open label, single-site, first-in-human, dose-escalation Phase Ia study to assess safety and immunogenicity of the Plasmodium falciparum malaria vaccine candidate Pfs48/45 in Matrix-M adjuvant in healthy adults living…
- Trial name
- NCT05400746
- Testing
- Pfs48/45 in Matrix-M
- Where
- United Kingdom
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Psoriatic Arthritis
Multicentre ObservatioNal Initiative in Treat to Target Outcomes in Psoriatic Arthritis
MONITOR is a cohort study recruiting patients with a new diagnosis of psoriatic arthritis (PsA) which will establish outcomes using a pragmatic feasible 'treat to target' approach in a real-life clinic population.
- Trial name
- MONITOR (NCT03531073)
- Testing
- Methotrexate
- Where
- United Kingdom
- Volunteers
- 446 people
- Sponsor
- University of Oxford
Locally Advanced Non-Small Cell Lung Cancer
Atovaquone With Radical ChemorADIotherapy in Locally Advanced NSCLC
This is a phase I, open-label trial that will utilise a Time To Event Continual Reassessment Method (TiTE-CRM) to determine the maximum tolerated dose (MTD) of atovaquone in combination with concurrent CRT in NSCLC.
- Trial name
- ARCADIAN (NCT04648033)
- Testing
- Atovaquone Oral Suspension, Standard of care chemotherapy, Standard of care radiotherapy
- Where
- 3 sites in United Kingdom
- Volunteers
- 21 people
- Sponsor
- University of Oxford
Malaria, Vivax
Safety and Immunogenicity of Pvs25-IMX313/Matrix-M1 Vaccine
This is an open-label, single-centre, non-randomised, first-in-human Phase Ia study to assess the safety and immunogenicity of the Pvs25-IMX313 vaccine, administered in Matrix-M1 adjuvant.
- Trial name
- NCT05270265
- Testing
- Pvs25-IMX313/Matrix-M1
- Where
- United Kingdom
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Type 2 Diabetes Mellitus in Obese
REmote SUpport for Low-Carbohydrate Treatment of Type 2 Diabetes
Excess adiposity is a key causal factor in developing type 2 diabetes and weight loss improves glycaemia and can put diabetes in to remission. There is evidence that low carbohydrate diets also reduce glycaemia.
- Trial name
- RESULT (NCT04916314)
- Testing
- Low Carbohydrate diet
- Where
- United Kingdom
- Volunteers
- 115 people
- Sponsor
- University of Oxford
Psoriatic Arthritis
Severe Psoriatic Arthritis - Early intervEntion to Control Disease: the SPEED Trial
SPEED is a three arm interventional trial nested within a cohort (Trials Within Cohorts or TWiCs design). This tests more aggressive early therapy in patients newly diagnosed with moderate to severe PsA.
- Trial name
- SPEED (NCT03739853)
- Testing
- Methotrexate, Sulfasalazine, Leflunomide
- Where
- United Kingdom
- Volunteers
- 192 people
- Sponsor
- University of Oxford
Stroke
Improving Sleep in Rehabilitation After Stroke
This study evaluates the efficacy of digital cognitive behavioural therapy for insomnia (Sleepio) in chronic stroke survivors. Half of the participants will receive access to the digital (online) programme, half will receive a…
- Trial name
- INSPIRES (NCT04272892)
- Testing
- Digital cognitive behavioural therapy for insomnia, Sleep hygiene information
- Where
- United Kingdom
- Volunteers
- 86 people
- Sponsor
- University of Oxford
Malaria,Falciparum
Safety and Immunogenicity of the Malaria Vaccine, R21/MatrixM, in Healthy Thai Adults
Malaria remains one of the leading causes of morbidity and mortality worldwide. Plasmodium falciparum is a complex pathogen with numerous immune evasion mechanisms which has added layers of complexity to the development of safe…
- Trial name
- R21/Matrix-M (NCT05252845)
- Testing
- R21/Matrix-M vaccination, DHA-PIP, PQ
- Where
- Thailand
- Volunteers
- 127 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Intermediate Risk Prostate Cancer, Castration-resistant Prostate Cancer
VAccination in Early and ADvanced Prostate caNCEr
This is a clinical trial of a new treatment for prostate cancer that is a type of vaccine that could be a new way to treat cancer.
- Trial name
- ADVANCE (NCT03815942)
- Testing
- ChAdOx1-MVA 5T4 vaccine, Nivolumab Infusion [Opdivo]
- Where
- 2 sites in United Kingdom
- Volunteers
- 23 people
- Sponsor
- University of Oxford
Diabetes Mellitus
ASCEND: A Study of Cardiovascular Events iN Diabetes
The purpose of this study is to determine whether 100mg daily aspirin versus placebo and/or supplementation with 1 gram daily omega-3 fatty acids or placebo prevents "serious vascular events" (i.e.
- Trial name
- NCT00135226
- Testing
- Aspirin, Omega-3 Ethyl Esters
- Where
- United Kingdom
- Volunteers
- 15,480 people
- Sponsor
- University of Oxford
Diabetic Retinopathy
Lowering Events in Non-proliferative Retinopathy in Scotland
LENS is a streamlined multicentre randomised placebo-controlled parallel-group trial investigating the effect of fenofibrate treatment on the progression of diabetic retinopathy/maculopathy.
- Trial name
- LENS (NCT03439345)
- Testing
- Fenofibrate 145 mg
- Where
- 16 sites in United Kingdom
- Volunteers
- 1,151 people
- Sponsor
- University of Oxford
Esophageal Cancer, Precancerous Condition
A Phase III, Randomized, Study of Aspirin and Esomeprazole Chemoprevention in Barrett's Metaplasia
RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of esomeprazole and aspirin may prevent esophageal cancer in patients with Barrett's metaplasia.
- Trial name
- AspECT (NCT00357682)
- Testing
- Esomeprazole, Aspirin
- Volunteers
- 2,557 people
- Sponsor
- University of Oxford
HIV
A Study to Assess Safety and Immunogenicity of Conserved Mosaic HIV-1 Vaccines
The object of the study is to assess the safety profile of candidate vaccines ChAdOx1.tHIVconsv1, MVA.tHIVconsv3 and MVA.tHIVcnsv4 administered sequentially in healthy HIV-1/2 negative adult volunteers.
- Trial name
- NCT04586673
- Testing
- ChAdOx1.tHIVconsv1 (C1), MVA.tHIVconsv3 (M3), MVA.tHIVconsv4 (M4)
- Where
- United Kingdom
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Malaria, Vivax
VAC069: A Study of Blood-stage Controlled Human P. Vivax Infection
This is a clinical study to assess the safety and feasibility of Plasmodium vivax (P. vivax) controlled blood-stage human malaria infection (CHMI), by inoculation using a newly created source of P. vivax malaria-infected blood.
- Trial name
- NCT03797989
- Testing
- P. vivax infected inoculum (parasitised red blood cells)
- Where
- United Kingdom
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Ebola
A Study of a New Vaccine Against Two Types of Ebola
An open-label, non-randomised, dose escalation, first-in-human, single centre, phase I clinical trial to determine the safety and immunogenicity of a bivalent ChAdOx1 vectored vaccine against Zaire and Sudan Ebola virus species…
- Trial name
- NCT05079750
- Testing
- ChAdOx1 biEBOV
- Where
- United Kingdom
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Prostate Cancer
IGF Inhibition With Xentuzumab Prior to Radical Prostatectomy
The WINGMEN trial aims to understand how a hormone-like protein called insulin-like growth factor (IGF) helps prostate cancers grow and become aggressive.
- Trial name
- WINGMEN (NCT05110495)
- Testing
- Xentuzumab
- Where
- United Kingdom
- Volunteers
- 27 people
- Sponsor
- University of Oxford
Locally Advanced Rectal Cancer
Chemoradiation With Enadenotucirev as a Radiosensitiser in Locally Advanced Rectal Cancer
The use of chemoradiotherapy (CRT), in combination with surgery is the standard of care in the treatment of locally advanced rectal cancer. However some patients don't respond well to radiation.
- Trial name
- CEDAR (NCT03916510)
- Testing
- Enadenotucirev, Capecitabine, Radiotherapy
- Where
- 4 sites in United Kingdom
- Volunteers
- 12 people
- Sponsor
- University of Oxford
Tuberculosis
Aerosol BCG Challenge Study in Historically BCG-vaccinated Volunteers
The purpose of this study is to evaluate the human clinical response to BCG challenge in historically BCG-vaccinated healthy adult volunteers. It will involve 12 participants in a controlled dose escalation.
- Trial name
- NCT04777721
- Testing
- BCG Danish
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Frozen Shoulder
The Anti-Freaze-F Study- "Anti-TNF for Treatment of Frozen Shoulder - a Feasibility Study"
Frozen shoulder is a common condition affecting approximately 9% of people aged 25-64 years. During the early phase the pain is usually unbearable and the later restriction in movement is severely limiting.
- Trial name
- Anti-FreazeF (NCT05299242)
- Testing
- Adalimumab Injection
- Where
- 4 sites in United Kingdom
- Volunteers
- 9 people
- Sponsor
- University of Oxford
Hip Osteoarthritis
Total Hip Replacement Performance & Assessment
This research study is focused upon assessing and optimising surgeon's performance during, and patient outcomes following, primary total hip replacement (THR) surgery.
- Trial name
- NCT04267172
- Testing
- Surgical simulation training in primary Total Hip Arthroplasty, No intervention: Surgical Resident Control Group, No Intervention: Consultant and Fellow Comparator Group
- Where
- United Kingdom
- Volunteers
- 243 people
- Sponsor
- University of Oxford